GUTS: Revita hits six-month endpoint as cuts extend cash runway into 2027
GUTS reports REMAIN-1 six-month results for Revita and a 45% workforce cut, with cash projected to last into Q2 2027, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
GUTS said participants in the REMAIN-1 study kept about 80% of the weight lost on GLP-1 drugs at the six-month endpoint, compared with 67% in the sham group, according to TradingView. The company is shifting its focus to Revita and plans to cut roughly 45% of its workforce.
Its cash is projected to last into Q2 2027, ahead of planned regulatory and clinical milestones.
why it matters
For investors, two things matter here: how long the cash will last and when the next milestones arrive. Workforce cuts usually signal an effort to lower spending, while the study results shape how fast the company can reach regulatory approval. This is news about one small company with no direct effect on the broader market.
market impact
GUTS: spending cuts and a longer cash runway are the key factors for the company's shares
tags
instruments
sources
- GUTS: Revita met its six-month pivotal endpoint as spending cuts extend runway into Q2 2027 — TradingView, 12 November 2026 at 21:08 UTC
- GUTS: REMAIN-1 met its six-month endpoint as Revita-focused cuts extend runway to 2027 milestones — TradingView, 12 November 2026 at 22:39 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗